Search Results
You are looking at 1 - 1 of 1 items for
- Author: Arja Pasternack x
- Refine by access: All content x
Search for other papers by Audrey Ziverec in
Google Scholar
PubMed
Search for other papers by Marie Chanal in
Google Scholar
PubMed
Search for other papers by Perrine Raymond in
Google Scholar
PubMed
Endocrinology Department, “C.I. Parhon” National Institute of Endocrinology, Bucharest, Romania
Search for other papers by Mirela Diana Ilie in
Google Scholar
PubMed
Search for other papers by Dario De Alcubierre in
Google Scholar
PubMed
Search for other papers by Arja Pasternack in
Google Scholar
PubMed
Search for other papers by Olli Ritvos in
Google Scholar
PubMed
Faculté de Médecine Lyon Est, Université Lyon 1, Lyon, France
Department of Endocrinology, Reference center for rare pituitary disease (HYPO), Groupement Hospitalier EST, Hospices Civils de Lyon, University of Lyon, Lyon, France
Search for other papers by Gerald Raverot in
Google Scholar
PubMed
Search for other papers by Philippe Bertolino in
Google Scholar
PubMed
Pituitary tumours are benign neoplasms that derive from hormone-producing cells of the pituitary gland. While medical treatments have emerged for most subtypes, gonadotroph tumours that express follicle-stimulating hormone (FSH) and/or luteinizing hormone still lack therapeutic options apart from surgery and radiotherapy. Activin ligands are physiological regulators of production and secretion of FSH by gonadotroph cells, but their role in gonadotroph tumourigenesis remains little explored. Using the LβT2 mouse gonadotroph cell line which produces FSH under activin stimulation, we first tested whether subcutaneous xenografts of LβT2 cells resulted in tumour formation in Rag2KO mice. Histological analysis confirmed the presence of LβT2 tumours with endothelial cells and macrophages in their microenvironment. FSH expression was found in a subset of clusters of LβT2 cells in the tumours. We subsequently addressed the consequences of targeting activin signalling via injection of a soluble activin decoy receptor (sActRIIB-Fc). sActRIIB-Fc treatment resulted in significantly decreased LβT2 tumour volume. Reduced Smad2 phosphorylation as well as inhibition of tumour-induced FSH production confirmed the efficient targeting of activin-downstream signalling in treated tumours. More interestingly, treated tumours showed significantly fewer endothelial cells associated with reduced Vegfa expression. In vitro treatment of LβT2 cells with sActRIIB-Fc had no effect on cell proliferation or apoptosis, but Vegfa expression was inhibited, pointing to a likely paracrine effect of LβT2 cells on endothelial cells through activin-mediated Vegfa regulation. Further in vitro and in vivo studies are now needed to pinpoint the exact roles of activin signalling in these processes prior to translating these observations to the clinic.
